FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex–driven autoimmunity
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
IgG immune complexes (ICs) promote autoimmunity through binding fragment crystallizable (Fc) γ-receptors (FcγRs). Of these, the highly prevalent FcγRIIa (CD32a) histidine (H)-131 variant (CD32aH) is strongly linked to human autoimmune diseases through unclear mechanisms. We show that, relative to the CD32a arginine (R)-131 (CD32aR) variant, CD32aH more avidly bound human (h) IgG1 IC and formed a ternary complex with the neonatal Fc receptor (FcRn) under acidic conditions. In primary human and mouse cells, both CD32a variants required FcRn to induce innate and adaptive immune responses to hIgG1 ICs, which were augmented in the setting of CD32aH. Conversely, FcRn induced responses to IgG IC independently of classical FcγR, but optimal responses required FcRn and FcγR. Finally, FcRn blockade decreased inflammation in a rheumatoid arthritis model without reducing circulating autoantibody levels, providing support for FcRn’s direct role in IgG IC-associated inflammation. Thus, CD32a and FcRn coregulate IgG IC-mediated immunity in a manner favoring the CD32aH variant, providing a novel mechanism for its disease association.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis.
Pettit, A. R., Ji, H., von Stechow, D., Müller, R., Goldring, S. R., Choi, Y., Benoist, C., & Gravallese, E. M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63016-7 · Cited by 807 · cited 1×
“Histopathological scoring of rear ankle joint inflammation and bone erosion on day 12 was by a blinded pathologist (J.N. Glickman) as described previously (Pettit et al., 2001).”
MethodAn Fc receptor structurally related to MHC class I antigens
Simister, N. E., & Mostov, K. E. (1989) · Nature · doi:10.1038/337184a0 · Cited by 729
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
Ulrichts, P., Guglietta, A., Dreier, T., van Bragt, T., Hanssens, V., Hofman, E., Vankerckhoven, B., Verheesen, P., Ongenae, N., Lykhopiy, V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97911 · Cited by 427 · cited 1×
“These studies have implications for current clinical trials of anti-FcRn and antiCD32a therapies (Chen et al., 2019; Kiessling et al., 2017; Ulrichts et al., 2018; Ling et al., 2019; Nixon et al., 2015; Blumberg et al., 2019), as they suggest that the therapeutic efficacy of these agents may derive in part from their…”
BackgroundEngineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407 · cited 1×
“2 nM at pH 6) pH relative to hIgG1WT and therefore can bind FcRn on the cell surface (Table S1; Vaccaro et al., 2005; Grevys et al., 2015).”
BackgroundCrystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex
Martin, W. L., West, A. P., Gan, L., & Bjorkman, P. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00230-1 · Cited by 391
Firan, M., Bawdon, R., Radu, C., Ober, R. J., Eaken, D., Antohe, F., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.8.993 · Cited by 330
Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
Kiessling, P., Lledo-Garcia, R., Watanabe, S., Langdon, G., Tran, D., Bari, M., Christodoulou, L., Jones, E., Price, G., Smith, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan1208 · Cited by 211
Prabhat, P., Gan, Z., Chao, J., Ram, S., Vaccaro, C., Gibbons, S., Ober, R. J., & Ward, E. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700337104 · Cited by 157
Cited by
The role of platelets in immune-mediated inflammatory diseases
Scherlinger, M., Richez, C., Tsokos, G. C., Boilard, E., & Blanco, P. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00834-4 · Cited by 346
The therapeutic age of the neonatal Fc receptor
Pyzik, M., Kozicky, L. K., Gandhi, A. K., & Blumberg, R. S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00821-1 · Cited by 288
Self-citationDelidakis, G., Kim, J. E., George, K., & Georgiou, G. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-082721-024500 · Cited by 87
The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement
Brinkhaus, M., Pannecoucke, E., van der Kooi, E. J., Bentlage, A. E. H., Derksen, N. I. L., Andries, J., Balbino, B., Sips, M., Ulrichts, P., Verheesen, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33764-1 · Cited by 51
Neonatal Fc receptor – biology and therapeutics
Bussel, J. B., Cines, D. B., & Blumberg, R. S. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2312718 · Cited by 49
Self-citation
Metadata
- Authors
- Hubbard, J. J., Pyzik, M., Rath, T., Kozicky, L. K., Sand, K. M. K., Gandhi, A. K., Grevys, A., Foss, S., Menzies, S. C., Glickman, J. N., Fiebiger, E., Roopenian, D. C., Sandlie, I., Andersen, J. T., Sly, L. M., Baker, K., & Blumberg, R. S.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-07-13
- Volume
- 217
- Issue
- 10
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W3043818679
- Cited by
- 48
- References
- 9
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.